Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK plus non-small cell lung cancer (NSCLC).
Stinchcombe, T; Doebele, RC; Wang, XF; Gerber, DE; Horn, L; Camidge, DR
Volume / Issue
Electronic International Standard Serial Number (EISSN)
International Standard Serial Number (ISSN)
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Conference Start Date
Conference End Date